Consistent with our observations of enhanced BCR pathway signaling, we found significantly increased representation of LYN, SYK, and JNK2 within kinome profiles of CLL cells from ibrutinib-treated patients. Here, MAPK9 is linked to B-cell chronic lymphocytic leukemia.